Latest Manufacturing And Supply Chain News

DroneShield has surpassed 4,000 systems sold globally, securing $7.9 million in new contracts from the U.S. Department of Defense and reporting record half-year revenue growth.

Amaero Ltd has locked in a five-year exclusive agreement to supply spherical refractory and titanium alloy powders to Titomic, bolstering advanced manufacturing capabilities for defense and aerospace sectors.

Telix Pharmaceuticals has received a Complete Response Letter from the FDA for its TLX250-CDx diagnostic agent, citing manufacturing concerns. The company plans immediate remediation and maintains its 2025 revenue guidance.

Amaero Ltd has secured A$50 million through a share placement and plans a further A$3 million via a Share Purchase Plan to fast-track growth initiatives aligned with U.S. defense and manufacturing re-shoring priorities.

Carnegie Clean Energy has made significant strides in advancing its wave energy technologies, signing key MOUs and achieving critical milestones in the ACHIEVE Programme during the June 2025 quarter.

Zimi Limited has completed production of its Smoke Connect safety range, progressed Matter Connect certification, and moved Senoa manufacturing to a new facility, while engaging investors for a capital raise.

Memphasys Limited has submitted its Felix™ sperm separation system for CE Mark approval, targeting Europe’s $5 billion IVF market, while expanding direct sales in Japan and validating its RoXsta™ oxidative stress diagnostic platform.

Li-S Energy has successfully produced Australia’s first lithium metal foils ahead of schedule at its Geelong facility, marking a major step in domestic battery manufacturing and supply chain sovereignty.

Cardiex Limited has announced a fully underwritten 1-for-4 entitlement offer at $0.04 per share, aiming to raise approximately $4.1 million to advance manufacturing and scale its supply chain. The offer closes on 20 June 2025, following a recent $2.4 million placement.

TruScreen Group Limited has announced a capital raising initiative involving Placement and Share Purchase Plan (SPP) Options, aiming to secure approximately NZ$3 million to fund strategic growth and working capital needs. The offer, subject to shareholder approval, includes up to 80.9 million Placement Options and 55.5 million SPP Options exercisable at A$0.02.

Clarity Pharmaceuticals has successfully imaged the first patient in its pivotal Phase III AMPLIFY trial for Cu-SAR-bisPSMA, a next-generation diagnostic agent targeting recurrent prostate cancer. This milestone sets the stage for potential FDA approval and broader clinical adoption.

Nanoveu Limited has launched a $2.7 million capital raising via a share placement and a substantial options offer, pending shareholder approval for securities issued to its Executive Chairman. The prospectus outlines key risks and the impact on the company’s capital structure.